Ved cellebaserede analyser havde lamivudinresistente HBV- stammer med enten rtM204I- mutationen eller rtL180M/ rtM204V - dobbeltmutationen ≥ 1. 000 gange mindre følsomhed for telbivudin.
In cell-based assays, lamivudine-resistant HBV strains containing either the rtM204I mutation or the rtL180M/ rtM204V double mutation had ≥ 1,000-fold reduced susceptibility to telbivudine.